Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Meadows

Allergy Birmingham, AL Medical Doctor

NPI 1811952849 CMS profile 37032

1600 7Th Ave S, Birmingham, AL 35233

Open in the dashboard

General payments

$203,503

577 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Meadows of Birmingham, AL is reported in the CMS Open Payments database as having received $203,503 across 577 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Allergy profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $838 18
2024 General $10,363 25
2023 General $48,130 80
2022 General $62,748 152
2021 General $40,680 124
2020 General $17,631 97
2019 General $23,113 81

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Meadows
  • Allergy median
  • Middle half of Allergy
  • National median

In program year 2025, general payments to John Meadows were reported at $838. Among 526 Allergy profiles paid that year, the median was $1,143 and the middle half received between $226 and $2,504.

Show as a table
Year John Meadows Allergy median Middle half National median
2019 $23,113 $506 $151–$1,337 $163
2020 $17,631 $409 $108–$1,162 $114
2021 $40,680 $549 $125–$1,485 $132
2022 $62,748 $666 $161–$1,594 $149
2023 $48,130 $780 $186–$1,916 $160
2024 $10,363 $1,031 $271–$2,196 $164
2025 $838 $1,143 $226–$2,504 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $54,061 124 payments
  2. Teva Pharmaceuticals USA, Inc. $51,495 92 payments
  3. Regeneron Healthcare Solutions, Inc. $23,421 60 payments
  4. Genzyme Corporation $20,277 45 payments
  5. Pfizer Inc. $19,530 39 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $16,771 13 payments
  7. Merck Sharp & Dohme Corporation $7,212 11 payments
  8. OptiNose US, Inc. $5,000 5 payments
  9. Novartis Pharmaceuticals Corporation $2,407 12 payments
  10. GlaxoSmithKline, LLC. $1,072 107 payments
  11. Other $2,259 69 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $142,100 69 payments
  2. Consulting Fee $36,019 13 payments
  3. Travel and Lodging $11,918 47 payments
  4. Food and Beverage $11,686 439 payments
  5. Honoraria $1,150 2 payments
  6. Grant $500 1 payment
  7. Education $130 6 payments
Products named General payments · program years 2019–2025
  1. TEZSPIRE $36,380 51 payments
  2. ProAir Digihaler $32,852 30 payments
  3. AirDuo RespiClick $30,970 16 payments
  4. ArmonAir Digihaler $27,657 22 payments
  5. DUPIXENT Inflammation And Immunology $23,549 62 payments
  6. DUPIXENT Immunology $22,238 48 payments
  7. FASENRA $15,556 36 payments
  8. EUCRISA $11,730 35 payments
  9. AirDuo Digihaler $9,189 63 payments
  10. CIBINQO $7,054 4 payments
  11. Other $12,729 238 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

577 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record